BRPI1008850A2 - [1,2,4]triazolo[1,5-a]piridinas como inibidores de quinase - Google Patents

[1,2,4]triazolo[1,5-a]piridinas como inibidores de quinase

Info

Publication number
BRPI1008850A2
BRPI1008850A2 BRPI1008850A BRPI1008850A BRPI1008850A2 BR PI1008850 A2 BRPI1008850 A2 BR PI1008850A2 BR PI1008850 A BRPI1008850 A BR PI1008850A BR PI1008850 A BRPI1008850 A BR PI1008850A BR PI1008850 A2 BRPI1008850 A2 BR PI1008850A2
Authority
BR
Brazil
Prior art keywords
triazolo
pyridines
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
BRPI1008850A
Other languages
English (en)
Portuguese (pt)
Inventor
Caroline Leriche
David Middlemiss
Eric Auclair
Jacques Le Roux
Original Assignee
Fovea Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42229029&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1008850(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fovea Pharmaceuticals filed Critical Fovea Pharmaceuticals
Publication of BRPI1008850A2 publication Critical patent/BRPI1008850A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI1008850A 2009-02-13 2010-02-09 [1,2,4]triazolo[1,5-a]piridinas como inibidores de quinase BRPI1008850A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09360013 2009-02-13
PCT/EP2010/051556 WO2010092041A1 (en) 2009-02-13 2010-02-09 [1, 2, 4] triazolo [1, 5 -a] pyridines as kinase inhibitors

Publications (1)

Publication Number Publication Date
BRPI1008850A2 true BRPI1008850A2 (pt) 2016-03-15

Family

ID=42229029

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008850A BRPI1008850A2 (pt) 2009-02-13 2010-02-09 [1,2,4]triazolo[1,5-a]piridinas como inibidores de quinase

Country Status (24)

Country Link
US (1) US20120041195A1 (enExample)
EP (1) EP2396324A1 (enExample)
JP (1) JP2012517971A (enExample)
KR (1) KR20110116160A (enExample)
CN (1) CN102317288A (enExample)
AR (1) AR075411A1 (enExample)
BR (1) BRPI1008850A2 (enExample)
CA (1) CA2751517A1 (enExample)
CL (1) CL2011001947A1 (enExample)
CO (1) CO6420343A2 (enExample)
CR (1) CR20110386A (enExample)
DO (1) DOP2011000248A (enExample)
EA (1) EA201101188A1 (enExample)
EC (1) ECSP11011250A (enExample)
HN (1) HN2011002095A (enExample)
IL (1) IL214426A0 (enExample)
MX (1) MX2011008549A (enExample)
NI (1) NI201100151A (enExample)
NZ (1) NZ594508A (enExample)
PE (1) PE20120110A1 (enExample)
SG (1) SG173610A1 (enExample)
TN (1) TN2011000379A1 (enExample)
WO (1) WO2010092041A1 (enExample)
ZA (1) ZA201105896B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20120044966A (ko) 2009-06-05 2012-05-08 세파론, 인코포레이티드 1,2,4-트리아졸로〔1,5ａ〕 피리딘 유도체의 제조 및 용도
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343295A1 (en) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
AR081960A1 (es) * 2010-06-22 2012-10-31 Fovea Pharmaceuticals Sa Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
MA35049B1 (fr) 2011-04-21 2014-04-03 Bayer Ip Gmbh Triazolopyridines
WO2012160029A1 (en) 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Substituted triazolopyridines
UA112096C2 (uk) 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
KR20130091464A (ko) 2012-02-08 2013-08-19 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체
WO2013135612A1 (en) 2012-03-14 2013-09-19 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
CN104603136B (zh) 2012-07-10 2017-06-27 拜耳医药股份有限公司 制备取代的三唑并吡啶的方法
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
LT3008062T (lt) 2013-06-11 2017-06-12 Bayer Pharma Aktiengesellschaft Pakeistųjų triazolpiridinų provaistų dariniai
EP4063371A1 (en) * 2019-11-22 2022-09-28 Medshine Discovery Inc. Pyrimidopyrrole spiro compounds and derivatives thereof as dna-pk inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056684B2 (ja) 1977-11-07 1985-12-11 東興薬品工業株式会社 点眼剤
US4271143A (en) 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4407792A (en) 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
EP0501523B1 (en) 1983-11-14 1997-04-09 Columbia Laboratories, Inc. Bioadhesive compositions
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
CA2386955A1 (en) 1999-11-22 2001-05-31 Warner-Lambert Company Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
EP1575959B1 (en) * 2002-12-18 2010-07-14 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
MXPA05007503A (es) 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
WO2005037285A1 (en) 2003-10-16 2005-04-28 Chiron Corporation 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer
NZ551027A (en) 2004-04-08 2011-01-28 Targegen Inc Benzotriazine inhibitors of kinases
PL382308A1 (pl) 2004-08-25 2007-08-20 Targegen, Inc. Związki heterocykliczne i sposoby stosowania
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CA2600531A1 (en) 2005-03-16 2006-09-28 Targegen, Inc. Pyrimidine compounds and methods of use
JP5079500B2 (ja) 2005-04-28 2012-11-21 協和発酵キリン株式会社 ２−アミノキナゾリン誘導体
JP2008543775A (ja) 2005-06-08 2008-12-04 ターゲジェン インコーポレーティッド 眼の障害を治療するための方法および組成物
JP2009531274A (ja) * 2005-12-07 2009-09-03 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド キナーゼ阻害性ピロロピリジン化合物
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
WO2008025821A1 (en) * 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
BRPI0718162A2 (pt) * 2006-10-20 2013-11-26 Irm Llc Composição e métodos para modulara os receptores c-kit e pdgfr
TW200829566A (en) 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds
CA2673003A1 (en) 2006-12-22 2008-07-03 Novartis Ag Quinazolines for pdk1 inhibition
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
BRPI0909945A2 (pt) * 2008-06-20 2015-07-28 Genentech Inc "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
US20100048557A1 (en) * 2008-06-20 2010-02-25 Bing-Yan Zhu Triazolopyridine JAK Inhibitor Compounds and Methods
WO2010010189A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010188A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010184A1 (en) * 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010018874A1 (en) * 2008-08-12 2010-02-18 Takeda Pharmaceutical Company Limited Amide compound
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法

Also Published As

Publication number Publication date
CO6420343A2 (es) 2012-04-16
IL214426A0 (en) 2011-09-27
NZ594508A (en) 2013-12-20
ECSP11011250A (es) 2011-10-31
SG173610A1 (en) 2011-09-29
CN102317288A (zh) 2012-01-11
KR20110116160A (ko) 2011-10-25
HN2011002095A (es) 2014-01-06
CL2011001947A1 (es) 2012-03-16
NI201100151A (es) 2012-10-03
US20120041195A1 (en) 2012-02-16
EA201101188A1 (ru) 2012-04-30
EP2396324A1 (en) 2011-12-21
DOP2011000248A (es) 2011-10-31
AR075411A1 (es) 2011-03-30
MX2011008549A (es) 2011-12-06
CR20110386A (es) 2011-12-02
ZA201105896B (en) 2012-03-28
PE20120110A1 (es) 2012-02-20
JP2012517971A (ja) 2012-08-09
WO2010092041A1 (en) 2010-08-19
CA2751517A1 (en) 2010-08-19
TN2011000379A1 (en) 2013-03-27

Similar Documents

Publication Publication Date Title
BRPI1008850A2 (pt) [1,2,4]triazolo[1,5-a]piridinas como inibidores de quinase
BR112012002110A2 (pt) derivados de pirrolo[1,2-b]piridazina como inibidores de janus cinase
DOP2011000388A (es) Carboxamidas 5-fenilo-[1,2,4] triazolo [1,5-a] piridina-2-il como inhibidores jak
BRPI0913580A2 (pt) pirrolopiridinas como inibidores de quinase
BRPI0908433A2 (pt) pirrolo[2,3-d]piridinas e empregos destas como inibidores tirosina cinase
CO7071124A2 (es) Pirazolo[1,5-a]piridina sustituida como inhibidores del receptor de cinasa tropomiosina (trk)
ES2598358T8 (es) Derivados de quinolina como inhibidores de PI3K quinasa
BRPI0913879A2 (pt) fenilpirazinonas como inibidores de quinase
BRPI0920135A2 (pt) imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BR112012029437A2 (pt) derivados de pirrolo[2,3-b]pirazina-7-carboxamida e seu uso como inibidores de jak e syk
BR112012029405A2 (pt) compostos macrocíclicos como inibidores de trk quinase
CO6801740A2 (es) Inhibidores de quinasa relacionados con pirrolo[2,3-d]pirimidina tropomiosina
LT2857404T (lt) Imidazo[1,2-b]piridazino dariniai, kaip kinazės inhibitoriai
BRPI0809998A2 (pt) Composto de imidazo[1,2-a] piridina como inibidores do receptor tirosina cinase
BRPI1012108A2 (pt) 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octano- ou heptano-nitrila como inibidores de jak
ME02397B (me) Pirazolo[1,5-a]pirimidini i -triazini kao antiviralni agensi
BR112013012965A2 (pt) derivados de imidazo (1,2-b] piridazina e imidazo [4, 5 -b] piridina como inibidores de jak
ZA201200982B (en) Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
BRPI1015038A2 (pt) derivados espiro azacíclicos como inibidores de hsl
IL224903A (en) Imidzo [c – 5,4] quinolines as DNA inhibitors
BRPI1011066A2 (pt) "pirazolopirimidinas e heterociclos relacionados como inibidores de quinase
ZA201108124B (en) Pyrrolo [2,3-b] pyridines which inhibit raf protein kinase
BR112013022917A2 (pt) derivados 3,4-dihidro-pirrolo[1,2-a]pirazino-1-ilamina úteis como inibidores de beta-secretase (bace)
CO6811848A2 (es) Derivados de (1,2,4) triazolo [4,3-a] quinoxalina como inhibidores de fosfodiesterasas
BRPI0906838A2 (pt) Pirimidinas como inibidores de quinase

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.